Compare FLXS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | PROK |
|---|---|---|
| Founded | 2001 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 417.1M |
| IPO Year | N/A | N/A |
| Metric | FLXS | PROK |
|---|---|---|
| Price | $40.06 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 27.8K | ★ 1.3M |
| Earning Date | 02-02-2026 | 11-10-2025 |
| Dividend Yield | ★ 2.00% | N/A |
| EPS Growth | ★ 64.53 | N/A |
| EPS | ★ 4.11 | N/A |
| Revenue | ★ $447,505,000.00 | $744,000.00 |
| Revenue This Year | $4.11 | $956.51 |
| Revenue Next Year | $3.04 | N/A |
| P/E Ratio | $9.71 | ★ N/A |
| Revenue Growth | ★ 6.00 | N/A |
| 52 Week Low | $29.38 | $0.46 |
| 52 Week High | $64.14 | $7.13 |
| Indicator | FLXS | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 50.16 | 45.29 |
| Support Level | $38.53 | $2.33 |
| Resistance Level | $41.34 | $2.59 |
| Average True Range (ATR) | 1.16 | 0.16 |
| MACD | -0.32 | -0.00 |
| Stochastic Oscillator | 34.81 | 33.96 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.